Trials / Completed
CompletedNCT02350764
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to closely examine tumor and blood samples from patients treated with nivolumab and ipilimumab in order to try to identify why some patients with lung cancers respond and why some patients do not.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nivolumab | |
| DRUG | pilimumab |
Timeline
- Start date
- 2015-01-20
- Primary completion
- 2023-09-25
- Completion
- 2023-09-25
- First posted
- 2015-01-30
- Last updated
- 2024-05-29
- Results posted
- 2024-05-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02350764. Inclusion in this directory is not an endorsement.